



[www.MedChemExpress.com](http://www.MedChemExpress.com)

Inhibitors, Agonists, Screening Libraries

# GPR84

## G protein coupled receptor 84

GPR84 is a G protein-coupled receptor for medium-chain fatty acids. GPR84 is a receptor for free fatty acids and can be potently activated by saturated medium-chain free fatty acids (MCFAs) like decanoic acid, undecanoic acid and lauric acid. GPR84, a receptor for medium-length free fatty acids is upregulated on protein level in LPS activated tolerant CD14<sup>+</sup> monocytes and THP-1 cells.


GPR84 is activated by MCFAs with the hydroxyl group at the 2- or 3-position more effectively than nonhydroxylated MCFAs. GPR84 is now considered to be a member of FFA-sensing GPCRs. MCFAs with carbon chain lengths of 9–14 activate GPR84, coupling primarily to a pertussis toxin (PTX)-sensitive G<sub>i/o</sub> pathway. GPR84 should be a proinflammatory receptor and may be a novel, attractive target for treating chronic low grade inflammation associated-diseases.

## GPR84 Agonists & Antagonists

### 6-OAU (GTPL5846)

Cat. No.: HY-12764

6-OAU(GTPL5846; 6-n-octylaminouracil) is a surrogate agonist of GPR84; activates human GPR84 in the presence of Gqi5 chimera in HEK293 cells with an EC50 of 105 nM in the PI assay.




**Purity:** 99.94%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

### GLPG1205

Cat. No.: HY-135303

GLPG1205 is potent, selective and orally active GPR84 (a G-protein-coupled receptor) antagonist with a favorable PK/PD profile. GLPG1205 has anti-inflammatory activity and is used for the treatment of pulmonary fibrosis.




**Purity:** 99.66%  
**Clinical Data:** Phase 2  
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### GPR84 antagonist 8

Cat. No.: HY-112562

GPR84 antagonist 8 is a selective GPR84 antagonist.




**Purity:** 99.96%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

### Setogepram

(PBI-4050)

Cat. No.: HY-100775A

Setogepram (PBI-4050) acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84. Setogepram (PBI-4050) decreases renal, liver and pancreatic fibrosis. Setogepram (PBI-4050) exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions.




**Purity:** >98%  
**Clinical Data:** Phase 3  
**Size:** 1 mg, 5 mg

### Setogepram sodium salt

(PBI-4050 sodium salt)

Cat. No.: HY-100775

Setogepram sodium salt (PBI-4050 sodium salt) acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84. Setogepram sodium salt decreases renal, liver and pancreatic fibrosis.



**Purity:** 99.65%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg